LSNE Contract Manufacturing Announces Manufacturing Agreement with Selecta Biosciences, Inc.

BEDFORD, N.H., May 24, 2017 /PRNewswire/ -- LSNE Contract Manufacturing announced today that they have signed a manufacturing supply agreement with Selecta Biosciences, Inc. Selecta is a clinical-stage biopharmaceutical company focused on utilizing its Synthetic Vaccine Particle (SVP™) platform to develop biologic therapies for rare and serious diseases that avoid the immune responses that compromise efficacy and lead to life-threatening complications. To support the development of these products, LSNE will provide Drug Substance manufacturing and fill/finish services.

"We are very excited to expand our existing relationship with Selecta.  Our expertise in development and GMP manufacturing makes us a strong partner for their project," said Matthew Halvorsen, President and CEO of LSNE.  "We look forward to working with their team on the late stage clinical programs, as well as future commercial manufacturing."

"Selecta is focused on ensuring that it has the right processes and partners as we advance our lead program, SEL-212, through the clinic and toward the commercial stage," said Lloyd Johnston, Ph.D., Chief Operating Officer of Selecta. "We are happy to have LSNE's support as a clinical and commercial manufacturer of SVP-Rapamycin for SEL-212 and future product candidates."

About LSNE Contract Manufacturing
LSNE Contract Manufacturing is a contract development and manufacturing organization with facilities located in Bedford and Manchester, NH.  LSNE has been providing lyophilization services to the pharmaceutical, biotechnology and medical device industries since 1997- specializing in a wide range of services such as process development and cGMP fill/finish and lyophilization.  Through the thoughtful integration of three manufacturing facilities, qualified staffing and a proven regulatory history, LSNE is strategically positioned to provide uninterrupted material for clinical through commercial supply. LSNE offers both the flexible approach commonly required with research and development scale projects, as well as the cGMP framework necessary for late stage clinical and commercial manufacturing.  Our experienced development, operations, quality and project management teams work in unison to evaluate our client's project objectives and to recommend an optimal path forward to achieve easier regulatory submissions and a faster time to market.

Contact: Christine Palus, [email protected], 603-668-5763

SOURCE Lyophilization Services of New England, Inc.

Related Links

http://www.lyophilization.com